This issue features full coverage of the 2015 ASH Annual Meeting and a look at how hematology is going mobile.
This issues features a sneak preview of the upcoming ASH Annual Meeting, debates whether IVC filters should still be inserted into thrombosis management guidelines, and has an in-depth focus on the how ABIM is still working to address concerns about the MOC program.
This issue features a look at adapting to scientific meeting climate change and coverage from the 15th International Myeloma Workshop.
This special issue of ASH Clinical News features updates in the world of multiple myeloma, including treatment options, advancements in understanding the disease, and looking ahead to the landscape of care.
This issue features coverage from the ASH Meeting on Hematologic Malignancies that took place in Chicago, IL. Our feature on big data reveals its potential to revolutionize healthcare, and our Editor's Corner gives an in-depth look at putting together a presentation for the upcoming ASH Annual Meeting.
In this issue, we look at the problem of physician burnout, follow a day in the life of a hem/onc APP, and examine the work-life spectrum.
This month, we take a behind-the-scenes look at guideline development, debate the length of anticoagulation for cancer-associated thrombosis, and report on the latest hematologic research from the American Society of Clinical Oncology annual meeting and the International Society on Thrombosis and Haemostasis 2015 Congress.
This month, we uncover the potential pitfalls of precision medicine, report on the latest hematologic research from the American Society of Clinical Oncology annual meeting and European Hematology Association Congress, and more.
This month, we take an in-depth look at the work that hematology advocates are doing, the latest research from Blood, and the latest hematology/oncology news.
This issue features a look at new tactics for fighting the cancer drug pricing bloat, a debate on fludarabine in CLL, a report from ASH’s Sickle Cell Disease Summit, and more.